{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:09:26Z","timestamp":1761962966733,"version":"3.41.2"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.transci.2025.104171","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T21:07:48Z","timestamp":1749157668000},"page":"104171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["When should I use filgrastim after autologous transplantation in MM patients?"],"prefix":"10.1016","volume":"64","author":[{"given":"S\u00fcleyman","family":"Arslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhami","family":"Berber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Kuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emin","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soykan","family":"Bi\u00e7im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulvahap","family":"Pinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib1","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"10.1016\/j.transci.2025.104171_bib2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.transci.2025.104171_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.transci.2025.104171_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.transci.2025.104171_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","article-title":"Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey","volume":"57","author":"Passweg","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"10.1016\/j.transci.2025.104171_bib6","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m\u00b2 vs melphalan 100 mg\/m\u00b2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2025.104171_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2025.104171_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103931","article-title":"Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose","volume":"63","author":"Lanza","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"10.1016\/j.transci.2025.104171_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.bmt.1702033","article-title":"Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF","volume":"24","author":"Offidani","year":"1999","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2025.104171_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1700621","article-title":"Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation","volume":"19","author":"Kolbe","year":"1997","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00365540802454706","article-title":"Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome","volume":"41","author":"Hamalainen","year":"2009","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"10.1016\/j.transci.2025.104171_bib12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMct1210890","article-title":"Colony-stimulating factors for febrile neutropenia during cancer therapy","volume":"368","author":"Bennett","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.transci.2025.104171_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.exphem.2005.11.013","article-title":"Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation","volume":"34","author":"Vanstraelen","year":"2006","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.transci.2025.104171_bib14","doi-asserted-by":"crossref","first-page":"696.e1","DOI":"10.1016\/j.jtct.2023.08.021","article-title":"Revisiting the utility of granulocyte colony-stimulating factor post-autologous hematopoietic stem cell transplantation for outpatient-based transplantations","volume":"29","author":"Portuguese","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12288-018-0966-5","article-title":"Pegfilgrastim: more cost effective and equally efficacious option as compared to filgrastim in autologous stem cell transplant","volume":"35","author":"Sheth","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"10.1016\/j.transci.2025.104171_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1600-0609.2006.00736.x","article-title":"Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients","volume":"77","author":"Martino","year":"2006","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.transci.2025.104171_bib17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ctr.12637","article-title":"Filgrastim vs TBO-filgrastim to reduce duration of neutropenia after autologous hematopoietic stem cell transplantation","volume":"29","author":"Trifilio","year":"2015","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-010-1036-8","article-title":"Pegfilgrastim reduces hospitalization and engraftment time compared to filgrastim in multiple myeloma patients","volume":"90","author":"Samaras","year":"2011","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.transci.2025.104171_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-019-03901-w","article-title":"A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients","volume":"99","author":"Martino","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.transci.2025.104171_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hon.978","article-title":"Comparison of fixed dose pegfilgrastim and daily filgrastim in multiple myeloma autografted outpatients","volume":"29","author":"Ferrara","year":"2011","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.transci.2025.104171_bib21","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.bbmt.2015.05.024","article-title":"Tbo-filgrastim vs filgrastim during mobilization and engraftment for autologous stem cell transplantation","volume":"21","author":"Elayan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/16078454.2021.2003071","article-title":"Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients","volume":"26","author":"Wang","year":"2021","journal-title":"Hematology"},{"issue":"30","key":"10.1016\/j.transci.2025.104171_bib23","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transci.2025.104171_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.transci.2025.104171_bib25","first-page":"839","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia after bendamustine plus rituximab in indolent NHL","volume":"25","author":"Cerchione","year":"2017","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.transci.2025.104171_bib26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.transci.2025.104171_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"Autologous bone marrow transplantation vs chemotherapy in multiple myeloma: a prospective randomized trial","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.transci.2025.104171_bib28","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.transci.2025.104171_bib29","first-page":"3471","article-title":"Transplantation for multiple myeloma: who, when, how often?","volume":"102","author":"Vesole","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2025.104171_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: a systematic review","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.transci.2025.104171_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13114","article-title":"Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma","volume":"21","author":"Rahman","year":"2019","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.transci.2025.104171_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bmt.1704724","article-title":"Lenograstim after autologous PBPC transplant: a double-blind randomized trial","volume":"34","author":"Schmitz","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1016\/j.transci.2025.104171_bib33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1703539","article-title":"The role of G-CSF in the post-transplant period","volume":"29","author":"Hornedo","year":"2002","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.transci.2025.104171_bib34","first-page":"1274","article-title":"Benefits of G-CSF after stem cell transplant in children: a randomized trial","volume":"87","author":"Dallorso","year":"2002","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.transci.2025.104171_bib35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bmt.1703538","article-title":"A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation","volume":"29","author":"de Azevedo","year":"2002","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2025.104171_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1468948","article-title":"The impact of delayed versus early administration of granulocyte colony-stimulating factor following autologous hematopoietic stem cell transplantation on transplantation outcome","volume":"14","author":"Mahdizadeh","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.transci.2025.104171_bib37","first-page":"533","article-title":"Delayed G-CSF post autologous transplant: a randomized study","volume":"17","author":"Faucher","year":"1996","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"10.1016\/j.transci.2025.104171_bib38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bmt.1701469","article-title":"G-CSF starting day 1 vs day 7 post-autologous transplant: a randomized trial","volume":"22","author":"Bence-Bruckler","year":"1998","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.transci.2025.104171_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.09.012","article-title":"G-CSF vs no G-CSF after autologous transplant: a randomized trial","volume":"28","author":"Grosso","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"10.1016\/j.transci.2025.104171_bib40","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1080\/10428194.2017.1318436","article-title":"G-CSF improves safety when started day 1 post-transplant in multiple myeloma","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.transci.2025.104171_bib41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/10781552221080710","article-title":"Day 4 vs day 12 G-CSF after allogeneic transplant","volume":"28","author":"Hatch","year":"2022","journal-title":"J Oncol Pharm Pr"},{"key":"10.1016\/j.transci.2025.104171_bib42","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1182\/blood-2019-130914","article-title":"Early vs delayed filgrastim post-ASCT in multiple myeloma: real-world single center data","volume":"134","author":"Monge","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2025.104171_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.transci.2025.104171_bib44","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus G-CSF alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:17:42Z","timestamp":1753352262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1473050225001089"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104171","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When should I use filgrastim after autologous transplantation in MM patients?","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104171"}}